← Every company
Supernus Pharmaceuticals Inc Patents
What Supernus Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
SUPN on carbonthat →Filings on file
24
Granted
3
Still pending
21
Filed under
4 names
24 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINESC07C 217/34, C07D 265/30, B01J 31/0239, B01J2231/347, B01J2231/348, B01J2531/002, C07B2200/07, C07C 213/00, C07C 217/32, C07C 309/66, C07C 309/73Filed as Supernus Pharmaceuticals, Inc.2025-11-25Yanjun Sun | pending |
| METHODS OF TREATMENT USING AN MTORC1 MODULATORA61K 31/197, A61K 31/198, A61P 25/24, A61K 9/0053Filed as Supernus Pharmaceuticals, Inc.2025-10-21Steven Leventer | pending |
| METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOFC07D 265/30, A61P 25/20, A61P 25/32, A61P 7/12, A61P 25/24, A61P 25/00, A61P 25/26, A61P 13/00, C07C 215/08, C07C 217/34, C07D 265/32Filed as Supernus Pharmaceuticals, Inc.2025-09-15Likan LIANG | pending |
| PROCESS FOR PRODUCING A GABA RECEPTOR MODULATORFiled as SAGE THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF SUPERNUS PHARMACEUTICALS, INC.2025-09-02STEPHEN COLLIER | pending |
| FORMULATIONS OF VILOXAZINEA61K 31/5375, A61P 25/24, A61P 25/00, A61K 9/00, A61K 9/146, A61K 9/2054, A61K 9/485, A61K 9/4866, A61K 9/50Filed as Supernus Pharmaceuticals, Inc.2025-08-21Michael L. Vieira | pending |
| MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOFC07C 229/12, C07F 7/08, C07F 7/081, C07C2601/08, C07C2601/04, C07C2601/14, A61P 21/00, A61P 37/02, A61P 43/00, A61P 3/10, A61P 25/00, A61P 25/08, A61P 35/00, A61K 31/197, A61K 31/198, A61K 31/221, A61K 31/223, A61K 31/275, A61K 31/341, A61K 31/41, A61K 31/695, A61K 38/00, A61K 45/06, C07C 229/14, C07C 229/18, C07C 229/20, C07C 229/22, C07C 229/26, C07C 229/28, C07C 233/07, C07C 233/40, C07C 233/47, C07C 233/49, C07C 233/51, C07C 233/63, C07C 233/83, C07C 237/06, C07C 237/12, C07C 237/30, C07C 255/61, C07C 261/04, C07C 311/06, C07C 311/10, C07C 311/13, C07C 311/14, C07C 311/19, C07C 311/51, C07D 257/04, C07D 307/33Filed as Supernus Pharmaceuticals, Inc.2025-07-03Kristina Michelle Fetalvero | pending |
| MODULATORS OF mTORC1 ACTIVITY AND USES THEREOFA61K 31/198, C07C 229/20, A61P 25/14, A61P 25/24, A61P 25/00, A61K 9/0053, A61K 9/141, A61K 33/14, A61K 45/06, A61K2300/00Filed as Supernus Pharmaceuticals, Inc2025-04-30Eddine Saiah | pending |
| FORMULATIONS OF VILOXAZINEA61K 31/5375, A61P 25/24, A61P 25/00, A61K 9/00, A61K 9/146, A61K 9/2054, A61K 9/485, A61K 9/4866, A61K 9/50Filed as Supernus Pharmaceuticals, Inc.2025-04-07Michael L. Vieira | pending |
| METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)A61K 31/5375, A61K 31/00Filed as Supernus Pharmaceuticals, Inc.2025-04-07Christopher D. BREDER | pending |
| FORMULATIONS OF VILOXAZINEA61K 31/5375, A61P 25/24, A61P 25/00, A61K 9/00, A61K 9/146, A61K 9/2054, A61K 9/485, A61K 9/4866, A61K 9/50Filed as Supernus Pharmaceuticals, Inc.2025-03-28Michael L. Vieira | pending |
| POLYMORPHIC COMPOUNDS AND USES THEREOFC07C 225/06, C07C 229/08, A61K 33/00, C07B2200/13Filed as Supernus Pharmaceuticals, Inc.2025-02-14Silvia Lenzini | pending |
| SUBSTITUTED DERIVATIVES OF ISOINDOLESC07D 487/04, A61K 31/4178, A61K 31/4188, A61K 31/496, C07D 207/20, C07D 233/14, C07D 403/06, C07D 405/06, C07D 405/10Filed as Supernus Pharmaceuticals, Inc.2025-01-22Gary L. Olson | 12454535 |
| FORMULATIONS OF MAZINDOLA61K 9/1635, A61K 9/0004, A61K 9/1611, A61K 9/1617, A61K 9/1652, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 9/2081, A61K 9/2813, A61K 9/282, A61K 9/2826, A61K 9/2853, A61K 9/2866, A61K 31/4045, A61K 31/407, A61K 31/4184, A61K 31/4188, A61P 25/14, A61P 43/00, A61P 3/04, A61P 25/00, A61K2300/00Filed as Supernus Pharmaceuticals, Inc.2025-01-13Argaw Kidane | pending |
| DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOFC07D 265/30, C07D 413/12, A61P 25/00, A61K 31/5375, A61K 31/5377, C07D 413/14Filed as Supernus Pharmaceuticals, Inc.2024-12-23Janak Khimchand Padia | pending |
| SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOFA61K 31/4188, A61P 3/04, A61P 19/02, A61P 25/00, A61P 35/00, A61K 31/404, A61K 31/4164, A61K 31/4178, A61K 31/496, A61K 31/55Filed as Supernus Pharmaceuticals, Inc.2024-09-27Gary L. Olson | pending |
| SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOFFiled as SUPERNUS PHARMACEUTICALS, INC.2024-09-27GARY L. OLSON | pending |
| METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)A61K 31/5375, A61K 31/00Filed as Supernus Pharmaceuticals, Inc.2024-09-20Christopher D. BREDER | pending |
| SUBSTITUTED DERIVATIVES OF ISOINDOLES AND USES THEREOFFiled as Supernus Pharmaceuticals, Inc.2024-08-14Gary L. Olson | pending |
| SUBSTITUTED DERIVATIVES OF ISOINDOLESFiled as SUPERNUS PHARMACEUTICALS, INC.2024-07-25GARY L. OLSON | pending |
| SUBSTITUTED DERIVATIVES OF ISOINDOLESC07D 487/04, A61K 31/4178, A61K 31/4188, A61K 31/496, C07D 207/20, C07D 233/14, C07D 403/06, C07D 405/06, C07D 405/10Filed as Supernus Pharmaceuticals, Inc.2024-07-25Gary L. Olson | pending |
| DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOFA61K 31/5375, C07D 265/30, A61P 25/22, A61P 25/24, A61P 25/00, A61K 31/5377, C07D 413/12, C07D 413/14Filed as Supernus Pharmaceuticals, Inc.2024-06-11Janak Khimchand Padia | 12747218 |
| DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOFFiled as SUPERNUS PHARMACEUTICALS, INC.2024-03-26JANAK KHIMCHAND PADIA | pending |
| DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOFA61K 31/5375, C07D 265/30, A61P 25/22, A61P 25/24, A61P 25/00, A61K 31/5377, C07D 413/12, C07D 413/14Filed as Supernus Pharmaceuticals, Inc.2024-03-26Janak Khimchand Padia | pending |
| DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOFC07D 265/30, C07D 413/12, A61P 25/00, A61K 31/5375, A61K 31/5377, C07D 413/14Filed as Supernus Pharmaceuticals, Inc.2024-01-18Janak Khimchand Padia | 12215097 |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on SUPN
Company overviewEverything on SUPN in one place, with the price.SEC filingsWhat SUPN's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat SUPN's own officers and directors buy and sell.Executive payWhat SUPN awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in SUPN.Funds holding itWhich funds and ETFs hold SUPN, and how big a bet.LobbyingWhat SUPN spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on SUPN's account, and who they worked for.